Last reviewed · How we verify
NCT06695494: EGGCUP
Enabling Genomic Testing in Cancer of Unknown Primary
trial testing Gene panel array in Cancer of Unknown Primary in 100 participants. Currently enrolling.
1 December 2026
Quick facts
| Lead sponsor | The Christie NHS Foundation Trust |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 August 2024 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2027 |
| Sites | 6 locations across United Kingdom |
Drugs / interventions tested
- Gene panel array
- Blood Sample Collection — full drug profile →
Conditions studied
- Cancer of Unknown Primary — all drugs for Cancer of Unknown Primary →
- Neoplasm, Unknown Primary — all drugs for Neoplasm, Unknown Primary →
Sponsor
The Christie NHS Foundation Trust
Who can join
16 and older, any sex, with Cancer of Unknown Primary or Neoplasm, Unknown Primary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cancer of Unknown Primary (CUP) is where cancer cells are found in the body but the place the cancer began is not known. It is the 6th leading cause of cancer death in the UK and the prognosis is poor with a median survival of 6-9 months. There is a higher than average incidence of CUP in the North West (NW) of England (population of 7.4 million). Precision medicine has transformed treatment strategies in known tumour types, however in CUP there remains an urgent need to better understand CUP molecular characteristics to establish potential roles for novel therapeutic strategies. Treatment options remain limited due to difficulties in determining the primary site of the tumour and the lack of access to validated biomarkers. Access to good-quality tissue for molecular profiling remains a huge challenge in CUP. The emergence of liquid biopsies (sequence DNA in a blood test) as a source of biomarkers is also gaining rapid ground and this study aims to explore the potential utility of liquid biopsies in CUP.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06695494
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Christie NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07183267 — Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Year · NA · not yet recruiting
- NCT07268339 — A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calme · Phase 3 · not yet recruiting
- NCT06965101 — To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compr · NA · recruiting
- NCT05903430 — A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION) · recruiting
- NCT07202260 — Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06695494 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Christie NHS Foundation Trust
- Last refreshed: 25 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06695494.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing